NAMS
NASDAQ · Biotechnology
Newamsterdam Pharma Co Nv
$31.40
+0.58 (+1.88%)
Financial Highlights (FY 2026)
Revenue
22.21M
Net Income
-201,203,432
Gross Margin
—
Profit Margin
-905.7%
Rev Growth
-38.7%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -1,002.9% | -902.6% | 8.2% | 7.5% |
| Profit Margin | -905.7% | -860.5% | 9.2% | 8.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 22.21M | 36.21M | 2.72B | 2.95B |
| Gross Profit | — | — | 806.06M | 871.89M |
| Operating Income | -222,761,690 | -326,843,040 | 222.76M | 221.95M |
| Net Income | -201,203,432 | -295,212,078 | 249.35M | 248.71M |
| Gross Margin | — | — | 29.6% | 29.6% |
| Operating Margin | -1,002.9% | -902.6% | 8.2% | 7.5% |
| Profit Margin | -905.7% | -860.5% | 9.2% | 8.4% |
| Rev Growth | -38.7% | -38.7% | +24.9% | +4.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.26B | 1.36B |
| Total Equity | — | — | 1.76B | 1.83B |
| D/E Ratio | — | — | 0.72 | 0.74 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -222,573,479 | -344,709,496 | 355.91M | 385.93M |
| Free Cash Flow | — | — | 147.67M | 144.03M |